ArticleTranslational lung cancer research2025

Long-term survival outcomes of lorlatinib in advanced anaplastic lymphoma kinase (ALK)-fusion positive non-small cell lung cancer.

Masahiro Morise et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.